Literature DB >> 24403599

Analysis of community- and hospital-acquired bacteraemia during a recent 5-year period.

Hee-Won Moon1, Young Jin Ko1, Seungman Park1, Mina Hur1, Yeo-Min Yun1.   

Abstract

There are sparse data concerning sex- and age-specific characteristics of community-acquired bacteraemia (CAB) and hospital-acquired bacteraemia (HAB). Between January 2008 and December 2012, we identified 2956 bacteraemia cases, which we classified as CAB, HAB or healthcare-associated bacteraemia (HCAB). Almost half of the pathogens were Escherichia coli in CAB patients. By contrast, Staphylococcus aureus was most frequent (16.2%) in HAB patients. HCAB showed mixed features of CAB and HAB. In CAB, E. coli was significantly more abundant in females than in males (56.9 vs 24.3%, respectively). This trend was most striking in young adults (20-39 years) (77.2% in females vs 11.4% in males). HAB cases showed greater heterogeneity in their associated pathogens. The extended-spectrum β-lactamase-positive rates of E. coli and Klebsiella pneumoniae, respectively, were 31.3 and 33.8% in HAB and 8.8 and 8.4% in CAB. The non-susceptibility rates of S. aureus to oxacillin were 37.4% in CAB and 73.0% in HAB. In conclusion, CAB and HAB showed different distributions of micro-organisms, and these distributions also differed with patient age and sex. In addition, antimicrobial susceptibility needs to be monitored separately.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24403599     DOI: 10.1099/jmm.0.069054-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  7 in total

1.  Low prevalence of rmpA and high tendency of rmpA mutation correspond to low virulence of extended spectrum β-lactamase-producing Klebsiella pneumoniae isolates.

Authors:  Wen-Liang Yu; Mei-Feng Lee; Hung-Jen Tang; Ming-Chung Chang; Yin-Ching Chuang
Journal:  Virulence       Date:  2015       Impact factor: 5.882

Review 2.  Antimicrobial Resistance Surveillance in Low- and Middle-Income Countries: Progress and Challenges in Eight South Asian and Southeast Asian Countries.

Authors:  Sumanth Gandra; Gerardo Alvarez-Uria; Paul Turner; Jyoti Joshi; Direk Limmathurotsakul; H Rogier van Doorn
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

3.  Community-acquired Pseudomonas aeruginosa bloodstream infection: a classification that should not falsely reassure the clinician.

Authors:  K L McCarthy; D L Paterson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-12-09       Impact factor: 3.267

4.  Bacterial bloodstream infections in a tertiary infectious diseases hospital in Northern Vietnam: aetiology, drug resistance, and treatment outcome.

Authors:  Vu Quoc Dat; Hieu Ngoc Vu; Hung Nguyen The; Hoa Thi Nguyen; Long Bao Hoang; Dung Vu Tien Viet; Chi Linh Bui; Kinh Van Nguyen; Trung Vu Nguyen; Dao Tuyet Trinh; Alessandro Torre; H Rogier van Doorn; Behzad Nadjm; Heiman F L Wertheim
Journal:  BMC Infect Dis       Date:  2017-07-12       Impact factor: 3.090

5.  Invasive infection caused by Klebsiella pneumoniae is a disease affecting patients with high comorbidity and associated with high long-term mortality.

Authors:  M Vading; P Nauclér; M Kalin; C G Giske
Journal:  PLoS One       Date:  2018-04-06       Impact factor: 3.240

6.  Population-based bloodstream infection surveillance in rural Thailand, 2007-2014.

Authors:  Julia Rhodes; Possawat Jorakate; Sirirat Makprasert; Ornuma Sangwichian; Anek Kaewpan; Thantapat Akarachotpong; Prasong Srisaengchai; Somsak Thamthitiwat; Supphachoke Khemla; Somkid Yuenprakhon; Wantana Paveenkittiporn; Anusak Kerdsin; Toni Whistler; Henry C Baggett; Christopher J Gregory
Journal:  BMC Public Health       Date:  2019-05-10       Impact factor: 3.295

7.  A retrospective analysis of community-onset bloodstream infections at a tertiary-care academic hospital in South Africa. Are current empiric antimicrobial practices appropriate?

Authors:  Vinitha Alex; Trusha Nana; Vindana Chibabhai
Journal:  Antimicrob Steward Healthc Epidemiol       Date:  2021-12-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.